In vivo antitumor activity of F 11782, a non-intercalating dual catalytic inhibitor of topoisomerases I and II, against a panel of human tumor xenografts

• Published in: Journal of experimental therapeutics & oncology Vol. 2; no. 4; p. 219
• Main Authors: Kruczynski, A, Ricome, C, Waud, W R, Hill, B T
• Format: Journal Article
• Language: English
• Published: United States 01.07.2002
• Subjects: Animals; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Cell Division - drug effects; Female; Humans; Mice; Mice, Nude; Naphthalenes - chemistry; Naphthalenes - pharmacology; Naphthalenes - therapeutic use; Neoplasm Transplantation; Neoplasms - drug therapy; Neoplasms - pathology; Pyrans - chemistry; Pyrans - pharmacology; Pyrans - therapeutic use; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transplantation, Heterologous; Xenograft Model Antitumor Assays
• ISSN: 1359-4117
• DOI: 10.1046/j.1359-4117.2002.01037.x

The marked in vivo antitumor activity of F 11782 against murine experimental tumors (Kruczynski et al., Br J Cancer 83: 1516-24, 2000) has now been confirmed in a panel of human tumor xenografts. Using an intermittent schedule of six administrations over 2 weeks, F 11782 showed major activity in four of eight xenograft models. Excellent activity was noted versus the CAKI-1 (renal) model, with regressions at the two highest doses, and marked activity against DLD-1 (colon) xenografts, also resulting in regressions at the MTD. Marked antitumor activity was also observed against DU 145 (prostate) and GLC4 (small-cell lung) tumors. At optimal doses, significant T/C values ranged from 3 to 29%, with significant growth delays of 1.5-5.6, without major body weight loss. This tumor growth inhibition induced by F 11782 was sustained with time for > or = 6 weeks post implant. In contrast, no real activity was recorded against NCI-H460 (non small-cell lung) tumors and only minor responses, with optimal T/C values of < 42%, noted in the rapidly proliferating SF-295 (CNS) and LOX IMVI (melanoma) xenografts or the chemo-refractory LoVo (colon) model. Overall, this study showing a 50% response rate with definite antitumor activity across a broad spectrum, coupled with its unique mechanistic profile, has prompted the further development of F 11782.